Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,501
  • Shares Outstanding, K 12,567
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,300 K
  • 60-Month Beta 1.13
  • Price/Sales 503.58
  • Price/Cash Flow N/A
  • Price/Book 4.18
Trade MNPR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -120.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.24 +0.57%
on 04/12/21
8.33 -36.74%
on 03/30/21
-2.33 (-30.66%)
since 03/12/21
3-Month
5.24 +0.57%
on 04/12/21
17.01 -69.02%
on 02/11/21
-1.00 (-15.95%)
since 01/12/21
52-Week
4.28 +23.13%
on 11/09/20
17.01 -69.02%
on 02/11/21
-1.54 (-22.58%)
since 04/09/20

Most Recent Stories

More News
Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

MNPR : 5.24 (-6.60%)
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

Validive Phase 2b/3 VOICE Clinical Trial Commenced

MNPR : 5.24 (-6.60%)
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

SIEGY : 83.1000 (-0.78%)
MNPR : 5.24 (-6.60%)
Monopar Therapeutics to Present at Upcoming Investor Conferences

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

MNPR : 5.24 (-6.60%)
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

ABT : 121.24 (+0.28%)
MNPR : 5.24 (-6.60%)
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive(R) for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

MNPR : 5.24 (-6.60%)
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for...

MNPR : 5.24 (-6.60%)
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for...

MNPR : 5.24 (-6.60%)
Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

AYTU : 6.92 (-4.29%)
MNPR : 5.24 (-6.60%)
Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

BAYRY : 15.8350 (-0.50%)
ABEO : 1.6000 (-2.44%)
BPMC : 93.68 (-0.51%)
MNPR : 5.24 (-6.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 6.03
2nd Resistance Point 5.94
1st Resistance Point 5.77
Last Price 5.24
1st Support Level 5.51
2nd Support Level 5.42
3rd Support Level 5.25

See More

52-Week High 17.01
Fibonacci 61.8% 12.15
Fibonacci 50% 10.65
Fibonacci 38.2% 9.14
Last Price 5.24
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar